Empagliflozin inhibits neointimal hyperplasia through attenuating endothelial-to-mesenchymal transition via TAK-1/NF-κB pathway

Abstract

Empagliflozin inhibits the inflammation-induced EndMT via the TAK-1/NF-κB signaling pathway.